Safety and Effectiveness of D-serine in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Negative symptoms, NMDA, Glutamate, Glycine
Eligibility Criteria
Inclusion Criteria: Structured Clinical Interview for DSM-III-R diagnosis of schizophrenia or schizoaffective disorder PANSS 3 factor negative symptom inclusion score greater than 20 prior to study entry PANSS total score between 60 and 110 Simpson-Angus Scale total score of 12 or less Calgary Depression Inventory total score of 10 and suicide score less than 2 No change in Clinical Global Impressions (CGI) Scale score prior to study entry Chlorpromazine (CPZ) equivalent of 1500 or less Willing to use an effective form of birth control throughout the study if sexually active Exclusion Criteria: High extrapyramidal symptom (EPS) levels Began, discontinued, or adjusted psychotropic medication within 2 weeks of study entry Taking investigational medication within 2 weeks of study entry Contraindication to study medication Serious or unstable medical illness Pregnant or breastfeeding Alcohol or drug abuse within 6 months of study entry Diagnosed with neurodegenerative disease or a seizure disorder History of a kidney impairment Currently taking clozapine Currently taking more than two antipsychotic medications Currently taking stimulants or cholinesterase inhibitors
Sites / Locations
- Yale University School of Medicine
- The Zucker Hillside Hospital
- The Nathan S. Kline Institute for Psychiatric Research
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
D-serine 30 mg/kg
D-serine 60 mg/kg
D-serine 120 mg/kg
D-serine 30 mg/kg
D-serine 60 mg/kg
D-serine 120 mg/kg